In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.
Rindi, G., Wiedenmann, B., Neuroendocrine neoplasia goes molecular — time for a change, <<NATURE REVIEWS. CLINICAL ONCOLOGY>>, 2019; 16 (3): 149-150. [doi:10.1038/s41571-018-0118-8] [http://hdl.handle.net/10807/133445]
Neuroendocrine neoplasia goes molecular — time for a change
Rindi, Guido;
2019
Abstract
In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
